Mild-to-moderate liver impairment has no influence on the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor.

被引：0

作者：

Eriksson, UG ^{[1
]}

Eriksson-Lepkowska, M ^{[1
]}

Ohlsson, L ^{[1
]}

Wåhlander, K ^{[1
]}

机构：

[1] AstraZeneca R&D, Molndal, Sweden

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 71卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：P99 / P99

页数：1

共 50 条

[1] No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor
Wåhlander, K
Eriksson-Lepkowska, M
Frison, L
Fager, G
Eriksson, UG
CLINICAL PHARMACOKINETICS, 2003, 42 (08) : 755 - 764
[2] No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor
Karin Wåhlander
Maria Eriksson-Lepkowska
Lars Frison
Gunnar Fager
Ulf G. Eriksson
Clinical Pharmacokinetics, 2003, 42 (8) : 755 - 764
[3] The pharmacokinetics and pharmacodynamics of ximelagatran in patients with mild-to-moderate impairment of liver function.
Eriksson, UG
Eriksson-Lepkowska, M
Ohlsson, L
Wåhlander, K
BLOOD, 2001, 98 (11) : 46A - 46A
[4] Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor
Linda C. Johansson
Lars Frison
Ulrika Logren
Gunnar Fager
David Gustafsson
Ulf G. Eriksson
Clinical Pharmacokinetics, 2003, 42 : 381 - 392
[5] Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor
Johansson, LC
Frison, L
Logren, U
Fager, G
Gustafsson, D
Eriksson, UG
CLINICAL PHARMACOKINETICS, 2003, 42 (04) : 381 - 392
[6] No pharmacokinetic or pharmacodynamic interaction between digoxin and ximelagatran, an oral direct thrombin inhibitor.
Sarich, TC
Schützer, KM
Wollbratt, M
Wall, U
Kessler, E
Eriksson, UG
BLOOD, 2003, 102 (11) : 127B - 127B
[7] Ximelagatran: An oral direct thrombin inhibitor
Dager, WE
Vondracek, TG
McIntosh, BA
Nutescu, EA
ANNALS OF PHARMACOTHERAPY, 2004, 38 (11) : 1881 - 1897
[8] No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran
Troy C. Sarich
Renli Teng
Gary R. Peters
Maria Wollbratt
Robert Homolka
Mia Svensson
Ulf G. Eriksson
Clinical Pharmacokinetics, 2003, 42 : 485 - 492
[9] No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran
Sarich, TC
Teng, RL
Peters, GR
Wollbratt, M
Homolka, R
Svensson, M
Eriksson, UG
CLINICAL PHARMACOKINETICS, 2003, 42 (05) : 485 - 492
[10] The pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran when administered with verapamil
Eriksson, UG
Dorani, H
Panfilov, S
Wall, U
Ohlsson, L
Sarich, TC
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1077 - 1077

← 1 2 3 4 5 →